Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Fiche publication


Date publication

septembre 2019

Journal

Clinical colorectal cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi, Dr VIENOT Angélique, Mme MEURISSE Aurélia


Tous les auteurs :
Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F

Résumé

FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcomes.

Mots clés

Clinical parameters, FOLFIRINOX, Laboratory parameters, Prognosis, Risk categories

Référence

Clin Colorectal Cancer. 2019 Sep 4;: